Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with<sup>131</sup>I-tositumomab
Rebecca Elstrom(Acentech (United States)), Mark Kaminski(Sheba Medical Center), Paul J. Christos(Cornell University), Kent A. Griffith(University of Michigan), Joseph R. Osborne(Cornell University), John P. Leonard(New York University), Peter Martin(Northwestern University), Anca M. Avram(University of Michigan), Ryan Putman(Michigan Medicine), Jia Ruan(Cornell University), Madhu Mazumdar(Memorial Sloan Kettering Cancer Center), Morton Coleman(Cornell University), Daniel Lebovic(Broad Institute), Stanley J. Goldsmith(United States Department of Health and Human Services), Richard R. Furman(Cornell University), June Greenberg(Cornell University), Erica Chapman(Michigan Medicine)
Cited by 14
Related Papers
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k